Carbon-Ion Beam Irradiation and the miR-200c Mimic Effectively Eradicate Pancreatic Cancer Stem Cells Under in vitro and in vivo Conditions

References

• Reames BN, Blair AB, Krell RW, et al. Management of locally advanced pancreatic cancer: results of an international survey of current practice. Ann Surg. 2019;273(6):1173–1181.
   Web of Science ®Google Scholar
• Ruarus A, Vroomen L, Puijk R, Scheffer H, Meijerink M. Locally advanced pancreatic cancer: a review of local ablative therapies. Cancers (Basel). 2018;10(1):16.
   PubMed Web of Science ®Google Scholar
• Gemenetzis G, Groot VP, Blair AB, et al. Survival in locally advanced pancreatic cancer after neoadjuvant therapy and surgical resection. Ann Surg. 2019;270(2):340–347.
   PubMed Web of Science ®Google Scholar
• Lambert A, Schwarz L, Borbath I, et al. An update on treatment options for pancreatic adenocarcinoma. Ther Adv Med Oncol. 2019;11:1758835919875568.
   Web of Science ®Google Scholar
• Goto Y, Nakamura A, Ashida R, et al. Clinical evaluation of intensity-modulated radiotherapy for locally advanced pancreatic cancer. Radiat Oncol. 2018;13:118.
   PubMed Web of Science ®Google Scholar
• Stefanowicz S, Stützer K, Zschaeck S, Annika Jakobi EG, Troost C. Comparison of different treatment planning approaches for intensity-modulated proton therapy with simultaneous integrated boost for pancreatic cancer. Radiat Oncol. 2018;13(1):228.
   PubMedGoogle Scholar
• Lambert A, Schwarz L, Borbath I, et al. An update on treatment options for pancreatic adenocarcinoma. Ther Adv Med Oncol. 2019;25(11):1758835919875568.
   Google Scholar
• Loehrer PJ, Sr YF, Cardenes H, et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an eastern cooperative oncology group trial. J Clin Oncol. 2011;29(31):4105–4112.
   PubMed Web of Science ®Google Scholar
• Shalini Moningi AS, Dholakia SP, Raman AB, et al. The role of stereotactic body radiation therapy for pancreatic cancer: a single-institution experience. Ann Surg Oncol. 2015;22(7):2352–2358.
   PubMed Web of Science ®Google Scholar
• Tozzi A, Comito T, Alongi F, et al. SBRT in unresectable advanced pancreatic cancer: preliminary results of a mono-institutional experience. Radiat Oncol. 2013;8:148.
   PubMed Web of Science ®Google Scholar
• Herman JM, Chang DT, Goodman KA, et al. Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. Cancer. 2015;121(7):1128–1137.
   PubMed Web of Science ®Google Scholar
• Krishnan S, Chadha AS, Suh Y, et al. Focal radiation therapy dose escalation improves overall survival in locally advanced pancreatic cancer patients receiving induction chemotherapy and consolidative chemoradiation. Int J Radiat Oncol Biol Phys. 2016;94(4):755–765.
   PubMed Web of Science ®Google Scholar
• Ben-Josef E, Schipper M, Francis IR, et al. A Phase I/II trial of intensity-modulated radiation (IMRT) dose escalation with concurrent fixed- dose rate gemcitabine (FDR-G) in patients with unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys. 2012;84(5):1166–1171.
   PubMed Web of Science ®Google Scholar
• Nichols RC, Huh S, Zuofeng L, Rutenberg M. Proton therapy for pancreatic cancer. World J Gastrointest Oncol. 2015;7(9):141–147.
   PubMed Web of Science ®Google Scholar
• Liermann J, Shinoto M, Syed M, Debus J, Herfarth K, Naumann P. Carbon ion radiotherapy in pancreatic cancer: a review of clinical data. Radiother Oncol. 2020;19(147):145–215.
   Google Scholar
• Shinoto M, Yamada S, Terashima K, et al.; Working Group for Pancreas Cancer. Carbon ion radiation therapy with concurrent gemcitabine for patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2016;95(1):498–504.
   PubMed Web of Science ®Google Scholar
• Kawashiro S, Yamada S, Isozaki Y, Nemoto K, Tsuji H, Kamada T. Carbon-ion radiotherapy for locoregional recurrence after primary surgery for pancreatic cancer. Radiother Oncol. 2018;129(1):101–104.
   PubMed Web of Science ®Google Scholar
• Kawashiro S, Yamada S, Okamoto M, et al. Multi-institutional study of carbon-ion radiotherapy for locally advanced pancreatic cancer: Japan Carbon-ion Radiation Oncology Study Group (J-CROS) study 1403 pancreas. Int J Radiat Oncol Biol Phys. 2018;101(5):1212–1221.
   PubMed Web of Science ®Google Scholar
• Sai S, Wakai T, Vares G, et al. Combination of carbon ion beam and gemcitabine causes unreparable DNA damage and death of radioresistant pancreatic cancer stem-like cells in vitro and in vivo. Oncotarget. 2015;6:5517–5535.
   PubMedGoogle Scholar
• Kong YW, Ferland-McCollough D, Jackson TJ, et al. microRNAs in cancer management. Lancet Oncol. 2012;13(6):e249–58.
   PubMed Web of Science ®Google Scholar
• Czochor JR, Glazer PM. microRNAs in cancer cell response to ionizing radiation. Antioxid Redox Signal. 2014;21(2):293–312.
   PubMed Web of Science ®Google Scholar
• Rodriguez A, Griffiths-Jones S, Ashurst JL, et al. Identification of mammalian microRNA host genes and transcription units. Genome Res. 2004;14(10A):1902–1910.
   PubMed Web of Science ®Google Scholar
• Cullen BR. Transcription and processing of human microRNA precursors. Mol Cell. 2004;16(6):861–865.
   PubMed Web of Science ®Google Scholar
• Takahashi RU, Prieto-Vila M, Kohama I, et al. Development of miRNA-based therapeutic approaches for cancer patients. Cancer Sci. 2019;110(4):1140–1147.
   PubMed Web of Science ®Google Scholar
• Vares G, Ahire V, Sunada S, et al. A multimodal treatment of carbon ions irradiation, miRNA-34 and mTOR inhibitor specifically control high-grade chondrosarcoma cancer stem cells. Radiother Oncol. 2020;S0167-8140:20.
   Google Scholar
• Kim EH, Kim JY, Kim MS, et al. Molecular mechanisms underlying the enhancement of carbon ion beam radiosensitivity of osteosarcoma cells by miR-29b. Am J Cancer Res. 2020;10(12):4357–4371.
   PubMed Web of Science ®Google Scholar
• Ma C, Huang T, Ding YC, et al. MicroRNA-200c overexpression inhibits chemoresistance, invasion and colony formation of human pancreatic cancer stem cells. Int J Clin Exp Pathol. 2015;8(6):6533–6539.
   PubMed Web of Science ®Google Scholar
• Byun Y, Choi YC, Jeong Y, et al. MiR-200c downregulates HIF-1α and inhibits migration of lung cancer cells. Cell Mol Biol Lett. 2019;24:28.
   PubMed Web of Science ®Google Scholar
• Yu J, Ohuchida K, Mizumoto K, et al. MicroRNA, hsa-miR-200c, is an independent prognostic factor in pancreatic cancer and its upregulation inhibits pancreatic cancer invasion but increases cell proliferation. Mol Cancer. 2010;9:169. doi:10.1186/1476-4598-9-16
   PubMed Web of Science ®Google Scholar
• Lo WL, Yu CC, Chiou GY, et al. MicroRNA-200c attenuates tumour growth and metastasis of presumptive head and neck squamous cell carcinoma stem cells. J Pathol. 2011;223(4):482–495.
   PubMed Web of Science ®Google Scholar
• Tang H, Song C, Ye F, et al. miR-200c suppresses stemness and increases cellular sensitivity to trastuzumab in HER2+ breast cancer.J. Cell Mol Med. 2019;23(12):8114–8127.
   PubMed Web of Science ®Google Scholar
• Rahimi M, Sharifi-Zarchi A, Zarghami N, Geranpayeh L, Ebrahimi M, Alizadeh E. Down-regulation of miR-200c and up-regulation of miR-30c target both stemness and metastasis genes in breast cancer. Cell J. 2020;21(4):467–478.
   PubMed Web of Science ®Google Scholar
• Karimi Dermani F, Amini R, Saidijam M, Najafi R. miR-200c, a tumor suppressor that modulate the expression of cancer stem cells markers and epithelial-mesenchymal transition in colorectal cancer. J Cell Biochem. 2018;119(7):6288–6295.
   PubMed Web of Science ®Google Scholar
• Park SM, Gaur AB, Lengyel E, Peter ME. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev. 2008;22(7):894–907.
   PubMed Web of Science ®Google Scholar
• Shimono Y, Zabala M, Cho RW, et al. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell. 2009;138(3):592–603.
   PubMed Web of Science ®Google Scholar
• Hambardzumyan D, Squartro M, Holland EC. Radiation resistance and stem-like cells in brain tumors. Cancer Cell. 2006;10:454–456.
   PubMed Web of Science ®Google Scholar
• Rich JN. Cancer stem cells in radiation resistance. Cancer Res. 2007;67:8980–8984).
   PubMed Web of Science ®Google Scholar
• Dingli D, Michor F. Successful therapy must eradicate cancer stem cells. Stem Cells. 2006;24:2603–2610.
   PubMed Web of Science ®Google Scholar
• Vermeulen L, de Sousa e Melo F, Richel DJ, Medema JP. The developing cancer stem-cell model: clinical challenges and opportunities. Lancet Oncol. 2012;13:e83–e89.
   PubMed Web of Science ®Google Scholar
• Wang B, Zheng J, Li R, et al. Long noncoding RNA LINC02582 acts downstream of miR-200c to promote radioresistance through CHK1 in breast cancer cells. Cell Death Dis. 2019;Oct(10):764.
   Google Scholar
• Koo T, Cho BJ, Kim DH, et al. MicroRNA-200c increases radiosensitivity of human cancer cells with activated EGFR-associated signaling. Oncotarget. 2017;8(39):65457–65468.
   PubMedGoogle Scholar
• Sun Q, Liu T, Yuan Y, et al. MiR-200c inhibits autophagy and enhances radiosensitivity in breast cancer cells by targeting UBQLN1. Int J Cancer. 2015;136(5):1003–1012.
   PubMed Web of Science ®Google Scholar
• Cortez MA, Valdecanas D, Zhang X, et al. Therapeutic delivery of miR-200c enhances radiosensitivity in lung cancer. Mol Ther. 2014;22(8):1494–1503.
   PubMed Web of Science ®Google Scholar
• Lin J, Liu C, Gao F, et al. miR-200c enhances radiosensitivity of human breast cancer cells. J Cell Biochem. 2013;114(3):606–615.
   PubMed Web of Science ®Google Scholar
• Shi L, Zhang S, Wu H, et al. MiR-200c increases the radiosensitivity of non-small-cell lung cancer cell line A549 by targeting VEGF-VEGFR2 pathway. PLoS One. 2013;8(10):e78344.
   PubMed Web of Science ®Google Scholar
• Feng ZM, Qiu J, Chen XW, et al. Essential role of miR-200c in regulating self-renewal of breast cancer stem cells and their counterparts of mammary epithelium. BMC Cancer. 2015;15:645.
   PubMed Web of Science ®Google Scholar
• Lim YY, Wright JA, Attema JL, et al. Epigenetic modulation of the miR-200 family is associated with transition to a breast cancer stem-cell-like state. J Cell Sci. 2013;126(Pt 10):2256–2266.
   PubMed Web of Science ®Google Scholar
• Jiang T, Dong P, Li L, et al. MicroRNA-200c regulates cisplatin resistance by targeting ZEB2 in human gastric cancer cells. Oncol Rep. 2017;38(1):151–158.
   PubMed Web of Science ®Google Scholar
• Wei W, Shi L, Chen W, et al. miR-200c regulates the proliferation, apoptosis and invasion of gastric carcinoma cells through the downregulation of EDNRA expression. Int J Mol Med. 2018;41(3):1619–1626.
   PubMed Web of Science ®Google Scholar
• Guo E, Wang Z, Wang S. MiR-200c and miR-141 inhibit ZEB1 synergistically and suppress glioma cell growth and migration. Eur Rev Med Pharmacol Sci. 2016;20(16):3385–3391.
   PubMed Web of Science ®Google Scholar
• Yuan D, Zheng S, Wang L, et al. MiR-200c inhibits bladder cancer progression by targeting lactate dehydrogenase A. Oncotarget. 2017;8(40):67663–67669.
   PubMedGoogle Scholar
• Cui X, Oonishi K, Tsujii H, et al. Effects of carbon ion beam on putative colon cancer stem cells and its comparison with X-ray. Cancer Res. 2011;71:3676–3687.
   PubMed Web of Science ®Google Scholar
• Oonishi K, Cui X, Hirakawa H, et al. Different effects of carbon ion beams and X-rays on clonogenic survival and DNA repair in human pancreatic cancer stem-like cells. Radiother Oncol. 2012;105:258–265.
   PubMed Web of Science ®Google Scholar
• Sai S, Vares G, Kim EH, et al. Carbon ion beam combined with cisplatin effectively disrupts triple negative breast cancer stem-like cells in vitro. Mol Cancer. 2015;14:166. doi:10.1186/s12943-015-0429-7
   PubMed Web of Science ®Google Scholar
• Sai S, Suzuki M, Kim EH, Hayahsi M, Yamamoto N, Miyamoto T. Effects of carbon ion beam alone or in combination with cisplatin on malignant mesothelioma cells in vitro. Oncotarget. 2018;9(19):14849–14861.
   PubMedGoogle Scholar
• Kim EH, Kim MS, Takahashi A, et al. Carbon-ion beam irradiation alone or in combination with zoledronic acid effectively kills osteosarcoma cells. Cancers. 2020;12:698.
   PubMed Web of Science ®Google Scholar
• Sai S, Kim EH, Suzuki M, Horimoto Y, Hayashi M. Combination of carbon-ion beam and dual tyrosine kinase inhibitor, lapatinib, effectively destroys HER2 positive breast cancer stem-like cells. Am J Cancer Res. 2020;10(8):2371–2386.
   PubMed Web of Science ®Google Scholar
• Reid G, Kao SC, Pavlakis N, et al. Clinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer. Epigenomics. 2016;Aug(8):1079–1085.
   Google Scholar
• Forterre A, Komuro H, Aminova S, Harada M. A comprehensive review of cancer MicroRNA therapeutic delivery strategies. Cancers (Basel). 2020;12(7):1852. doi:10.3390/cancers12071852
   PubMed Web of Science ®Google Scholar
• Bai Z, Wei J, Yu C, et al. Non-viral nanocarriers for intracellular delivery of microRNA therapeutics. J Mater Chem B. 2019;7:1209–1225.
   PubMed Web of Science ®Google Scholar
• Mansoori B, Silvestris N, Mohammadi A, et al. miR-34a and miR-200c have an additive tumor-suppressive effect on breast cancer cells and patient prognosis. Genes (Basel). 2021;12(2):267.
   PubMed Web of Science ®Google Scholar
• Reid G, Pel ME, Kirschner MB, et al. Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma. Ann Oncol. 2013;24(12):3128–3135.
   PubMed Web of Science ®Google Scholar
• Bushman FD. Retroviral integration and human gene therapy. J Clin Invest. 2007;117:2083–2086.
   PubMed Web of Science ®Google Scholar
• Kaban K, Salva E, Akbuga J. The effects of chitosan/miR-200c nanoplexes on different stages of cancers in breast cancer cell lines. Eur J Pharm Sci. 2016;95:103–110.
   PubMed Web of Science ®Google Scholar
• Fernandez CA, Rice KG. Engineered nanoscaled polyplex gene delivery systems. Mol Pharm. 2009;6:1277–1289.
   PubMedGoogle Scholar
• Ochiya T, Nagahara S, Sano A, Itoh H, Terada M. Biomaterials for gene delivery: atelocollagen-mediated controlled release of molecular medicines. Curr Gene Ther. 2001;1:31–52.
   PubMedGoogle Scholar
• Tkach M, Théry C. Communication by extracellular vesicles: where we are and where we need to go. Cell. 2016;164:1226–1232.
   PubMed Web of Science ®Google Scholar
• EL Andaloussi S, Mäger I, Breakefield XO, Wood MJ. Extracellular vesicles: biology and emerging therapeutic opportunities. Nat Rev Drug Discov. 2013;12:347–357.
   PubMed Web of Science ®Google Scholar